What's the problem? [Regulatives / Guidelines]

posted by kumarnaidu – Mumbai, India, 2017-07-11 16:43 (3266 d 19:10 ago) – Posting: # 17533
Views: 24,258

Hi all,
Recently we did pilot and pivotal (Partial reference replicate) studies for WHO and we got high variability (CV=32%). In the USFDA product specific guidance they have suggested 2x2 crossover design for this drug. Based on our prior experience can we perform reference replicate study or need to go as per guidance?:confused:

Kumar Naidu

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,570 registered users;
127 visitors (0 registered, 127 guests [including 12 identified bots]).
Forum time: 11:53 CEST (Europe/Vienna)

Science is simply common sense at its best that is,
rigidly accurate in observation, and
merciless to fallacy in logic.    Thomas Henry Huxley

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5